Angle has initiated its 200 people ovarian study which will use the company’s Parsortix and HyCEAD Ziplex platforms. Credit: kropekk_pl from Pixabay.

UK-based liquid biopsy company Angle has initiated the main phase of its ovarian cancer test study and enrolled its first patient.

Set to enrol a total of 200 subjects, the clinical verification study will evaluate the use of the company’s Parsortix and HyCEAD Ziplex platforms as a blood test to identify the presence of ovarian cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The University of Rochester Medical Center Wilmot Cancer Institute in the US is undertaking the study.

The test will detect the presence of ovarian cancer in women with a pelvic mass and evaluate the performance of the company’s combined platforms.

Angle noted that the combined Parsortix and HyCEAD Ziplex test will be carried out in a clinical setting and with clinical samples to gather circulating tumour cells and undertake multiplex RNA analysis.

Angle founder and chief executive Andrew Newland said: “We are excited about the start of the full clinical verification study to demonstrate the performance of our ovarian cancer test designed to support the launch of a clinical assay at a clinical laboratory and/or via a commercial partnership.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects a positive outcome which will aid in its plans to release a clinical assay to detect ovarian cancer in women who have an abnormal pelvic mass.

The assay is expected to have high specificity and a high sensitivity to cancer.

Angle plans to conclude the study in the first quarter of next year. The company claims to have no power over patient enrolment.

In June, Angle reported positive findings from clinical study ANG-002, which assessed its Parsortix system for the capture and harvesting of metastatic breast cancer cells.

Last October, the company reported positive results from a clinical study evaluating its Parsortix system for non-invasive prenatal testing (NIPT).